pentobarbital will reduce the extent or result of cobimetinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Avoid coadministration. Powerful or reasonable CYP3A inducers may minimize cobimetinib systemic exposure by >eighty% and minimize its efficacy. Acute or chro